Beta‐glucan enhanced killing of renal cell carcinoma micrometastases by monoclonal antibody G250 directed complement activation
Open Access
- 3 February 2004
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 109 (6), 900-908
- https://doi.org/10.1002/ijc.20029
Abstract
Metastases from renal cell carcinomas (RCC) are resistant to radiation and chemotherapy but are relatively immunogenic. We have investigated the possibility to eliminate human RCC micrometastases using MAb G250. G250 penetrates human micrometastases completely in a spheroid model and induces complement deposition rapidly on the outmost cell layers. However, complement dependent cytotoxicity (CDC) was barely detected using either 51chromium release assays or confocal microscopy, due to relatively low expression of the G250 antigen and the effect of membrane bound complement regulatory proteins. Addition of blocking anti-CD59 MAbs enhanced formation of C5b-9 and consequently complement mediated lysis (13%). Complement assisted cellular cytotoxicity (CACC) was not detectable, although the iC3b ligand and CR3 receptor were present on respectively target and effector cells. Addition of soluble β-glucan induced the killing of MAb and iC3b opsonized spheroids by effector cells (6–21%). Despite a lower affinity for G250 antigen, a bispecific anti-G250*anti-CD55 MAb enhanced cell killing in spheroids comparable to the parental G250 MAb. Our results suggest that complement-activating G250 in combination with anti-mCRP MAbs is able to kill human RCC cells in micrometastasis in vitro. For CACC the presence of CR3-priming β-glucan seems to be obligatory. In vivo, bi-MAb may be more effective as therapeutic agent due to its increased C5a generating properties.Keywords
This publication has 43 references indexed in Scilit:
- Novel therapies for renal cell carcinoma – an updateExpert Opinion on Investigational Drugs, 2003
- Thirteen‐year, long‐term efficacy of interferon 2α and interleukin 2‐based home therapy in patients with advanced renal cell carcinomaCancer, 2002
- EPIDERMAL GROWTH FACTOR RECEPTOR AND G250: USEFUL TARGET ANTIGENS FOR ANTIBODY MEDIATED CELLULAR CYTOTOXICITY AGAINST RENAL CELL CARCINOMA?Journal of Urology, 2002
- Monoclonal antibody therapy for solid tumorsCancer Treatment Reviews, 2000
- Anti-Renal-Cell Carcinoma Chimeric Antibody G250 Facilitates Antibody-Dependent Cellular Cytotoxicity with In Vitro and In Vivo Interleukin-2-Activated EffectorsJournal of Immunotherapy, 1996
- Limited loss of nine tumor‐associated surface antigenic determinants after tryptic cell dissociationCytometry, 1995
- Three-Dimensional Growth of Glial Cell Lines Affects Growth Factor and Growth Factor Receptor mRNA LevelsExperimental Cell Research, 1994
- Activation of human complement by mouse and mouse/human chimeric monoclonal antibodiesClinical and Experimental Immunology, 1993
- Inhibition of Experimental Pulmonary Metastasis of Lewis Lung Carcinoma by Orally Administered .BETA.-Glucan in Mice.CHEMICAL & PHARMACEUTICAL BULLETIN, 1991
- Formation and growth of multicellular spheroids of human originInternational Journal of Cancer, 1983